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Abstract
Predicting the efficacy of a drug for a given individual, using high-
dimensional genomic measurements, is at the core of precision medicine.
However, identifying features on which to base the predictions remains
a challenge, especially when the sample size is small. Incorporating ex-
pert knowledge offers a promising alternative to improve a prediction
model, but collecting such knowledge is laborious to the expert if the
number of candidate features is very large. We introduce a probabilistic
model that can incorporate expert feedback about the impact of ge-
nomic measurements on the sensitivity of a cancer cell for a given drug.
We also present two methods to intelligently collect this feedback from
the expert, using experimental design and multi-armed bandit models.
In a multiple myeloma blood cancer data set (n=51), expert knowledge
decreased the prediction error by 8%. Furthermore, the intelligent ap-
proaches can be used to reduce the workload of feedback collection to
less than 30% on average compared to a naive approach.
1 Introduction
In genomics-based personalized or precision medicine, large-scale screenings
and sequencing produce thousands of genomic and molecular features for
each sample. However, the data sets are small: typically only hundreds, or
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at most a thousand cell lines, and even fewer patients, are included in the
data sets. This is the case also for genomic cancer medicine, the focus of
this work, which includes gene expression, somatic mutation, copy number
variation and cytogenetic marker measurements characterizing ex vivo bone
marrow patient samples for the task of predicting sensitivity to a panel of
drugs. Although large-scale genomic studies in cancer have identified re-
current molecular events that predict prognosis and explain pathogenesis,
causal effects on drug response have been established for only a few of those
features. The limited data poses a challenge for learning predictive mod-
els from the data. The established statistical methods for finding predic-
tive features (biomarkers) and learning predictive models are similar across
omics-based data analysis tasks. Multivariate analysis of variance [1] is a
classical linear method. Recently, sparse regression models such as LASSO
and elastic net [1, 2] have become standard reliable benchmark methods,
and kernel methods enable finding more complex nonlinear combinations of
the features [3, 4].
Figure 1: Overview. Predictions in small sample size problems are improved
by asking experts in an elicitation loop. The system presents questions for
the expert sequentially to maximize performance with a minimal number of
questions, i.e., on a budget. The expert answers the questions by indicat-
ing whether a feature is relevant and in which direction in predicting the
response to a drug.
A natural way to solve the particular problems caused by a small sample
size is to measure more data. This is, however, often not an available option,
due to costs, risks, or the rarity of the disease. Statistical ways of alleviating
the problem are multitask learning [5, 4], which increases predictive power by
sharing statistical strength between multiple related outputs or data sets,
and incorporating biological prior knowledge. Biological prior knowledge
about cancer pathways has been used as side information for learning [3,
4], for feature selection [6, 7], or to modify regularization of, for instance,
an elastic net [8]. Although these methods improve the predictions, they
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sidestep the problem of what information to choose from the databanks,
and naturally cannot include knowledge not yet in the databanks.
A more rarely exploited alternative is to ask an expert. Prior elic-
itation techniques [9] have been used for constructing prior distributions
for Bayesian data analysis that take into account expert knowledge, and
hence can restrict the range of parameters to be later used in learning
models [10, 11, 12, 13]. These techniques focus on how to reliably elicit
knowledge, whereas in practice it is equally important to minimize the ef-
fort required from the expert. Interactive and sequential learning can help
by carefully deciding what to ask the user, and has been used, for instance,
for clustering [14, 15], learning of Bayesian networks [16], and for visualiza-
tion [17].
Very recently, interactive learning has been proposed for including ex-
pert knowledge in a prediction task, in a linear regression setting with a
small sample size. First indications that improvements are possible [18]
were obtained with strong assumptions on simulated experts. Human ex-
perts were included in two other studies [19, 20] on textual data, obtaining
improved predictions with a small number of expert feedbacks, for the tasks
of predicting user ratings, and predicting citation counts. The elicitation
techniques were based on Bayesian experimental design and a multi-armed
bandit user model, which helped the user solve the exploration-exploitation
dilemma [21] in giving feedback.
In this paper, we introduce sequential knowledge elicitation methods
to the precision medicine prediction task, illustrated in Figure 1. As a
case study to show the potential of the methods, we use drug sensitivity
prediction in patient samples, which is known to be very hard. We predict
drug responses of ex vivo cell samples from blood cancer patients, based
on mutation data and cytogenetics markers. Two well-informed experts are
asked to provide feedback about the relevance of features when predicting
sensitivity to specific targeted drugs, and about the direction of the putative
effects.
Our main contribution is to show for the first time that sequential expert
knowledge elicitation can improve predictive modeling in precision medicine.
Specifically, we show that
• expert knowledge elicitation improves the accuracy of drug sensitivity
predictions in the difficult case of predicting drug responses based
on patient’s somatic mutations and cytogenetic markers, crucial for
choosing which drug to prescribe to a patient in precision medicine,
• sequential expert knowledge elicitation reduces the number of queries
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required from the expert compared to naive approach with randomly
chosen queries.
These empirical results required four advances from recent [19, 20] methods
proposed for different elicitation tasks: Firstly, we extend a method pre-
viously used in automatic design of experiments to the challenging expert
knowledge elicitation task in precision medicine. In addition, we introduce
feedback on the direction of the putative effect and show that it is more ef-
fective in improving the drug sensitivity predictions than general relevance
feedback. We develop the bandit user model approach to incorporate bio-
logical information in the form of pathways and drug targets. Finally, we
extend the methods from univariate to multivariate outputs (sensitivity to
multiple drugs, with feedback given to (drug, feature) pairs).
2 Problem set-up
In cancer treatment, doctors need to choose which of the available drugs to
administer to new patients. Machine learning could be used to assist the
doctor in the choice by predicting the drug responses of patients from their
genomic features. The available patient data sets, however, are too small for
accurate learning of predictive models. Here we aim at improving the drug
response predictions in this challenging setting. In particular, we propose
sequential expert knowledge elicitation as a solution to the problem of drug
response prediction given a small sample size. In our specific case, data
from 51 blood cancer patients are available, with the number of considered
genomic features (mutations and cytogenetic markers) being 3032, and we
wish to predict the responses for 12 drugs.
Experts in blood cancer medicine have knowledge of biomarkers, and
could also associate other features to the drug responses based on their
experience. Unfortunately, the approach of naively querying each feature
for knowledge from the experts is burdensome given the large number of
features. Therefore, we introduce two sequential knowledge elicitation algo-
rithms that are able to choose the (drug, feature) pairs that have the highest
effect in improving the predictions, and compare their performance in this
precision medicine case.
We assume that the experts will be able to answer two types of ques-
tions regarding the effect of a feature to drug response. Firstly, if a feature
is relevant (or irrelevant) in predicting the drug response. This type of
feedback was used in [19] for textual data. In addition to that, the experts
may possess knowledge on the direction of the effect for a subset of relevant
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features. This directional feedback tells if a feature is positively or nega-
tively correlated with the drug response, extending the work in [20], where
the feedback was only on positive correlations and used in a textual data
application. The precise mathematical formulation of the effect of the two
feedback types to the prediction model will be given in Section 3.1.
3 Models and algorithms
In this section, we describe the proposed models and algorithms for sequen-
tial expert knowledge elicitation. First, we describe a sparse linear regression
model that is used to learn the relationship between genomic features and
drug responses, and which takes into account the elicited expert knowledge.
Then we introduce the two elicitation methods developed for the case study
in precision medicine.
3.1 Prediction model
Sparse linear regression models are used to predict the drug sensitivities
based on the genomic features. Let yn,d be the sensitivity of the nth patient
for drug d, and xn ∈ RM be the vector of the patient’s M genomic features.
We assume a Gaussian observation model:
yn,d ∼ N(w>d xn, σ2d),
where the wd ∈ RM are the regression weights and σ2d is the residual vari-
ance. A sparsity-inducing spike-and-slab prior [22, 23] is put on the weights:
wd,m ∼ γd,m N(0, τ2d,m) + (1− γd,m)δ0,
where γd,m is a binary variable indicating whether the mth feature is relevant
(i.e., wd,m drawn from a zero-mean Gaussian prior with variance τ
2
d,m) or
not (wd,m is set to zero via the Dirac delta spike δ0) when predicting for
the dth drug. The prior probability of relevance ρd controls the expected
sparsity of the model via the prior
γd,m ∼ Bernoulli(ρd).
The model is completed with the hyperpriors:
σ−2d ∼ Gamma(ασ, βσ),
ρd ∼ Beta(αρ, βρ),
τd,m ∼ Log-N(µ, ω2).
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Settings for the values of the hyperparameters are discussed in Section 4.1.
Expert knowledge is incorporated into the model via feedback observa-
tion models [19]. The relevance feedback f reld,m ∈ {0, 1} (0 denotes irrelevant,
1 relevant) of feature m for drug d follows
f reld,m ∼ γd,m Bernoulli(pireld ) + (1− γd,m) Bernoulli(1− pireld ),
where pireld is the probability of the expert being correct. For example, when
the mth feature for drug d is relevant in the regression model (i.e., γd,m = 1),
the expert would a priori be assumed to say f reld,m = 1 with probability pi
rel
d .
In the model learning , once the expert has provided the feedback based on
his or her knowledge, pireld effectively controls how strongly the model will
change to reflect the feedback.
The directional feedback fdird,m ∈ {0, 1} (0 denotes negative weight, 1
positive) follows
fdird,m∼I(wd,m≥0)Bernoulli(pidird )+I(wd,m<0)Bernoulli(1−pidird ),
where I(C) = 1 when the condition C holds and 0 otherwise, and pidird is
again the probability of the expert being correct. For example, when the
weight wd,m is positive, the expert would a priori be assumed to say f
dir
d,m = 1
with probability pidird . To simplify the model, we assume pid = pi
dir
d = pi
rel
d
and set a prior on pid as pid ∼ Beta(αpi, βpi). The prediction model and
learning are detailed in Appendix A.
3.2 Expert knowledge elicitation methods
The purpose of expert knowledge elicitation algorithms is to sequentially
choose queries to the expert, so that the improvement in predictions is max-
imized. In the case of genomic data, very few genes are known to be as-
sociated with drug responses, and therefore restricting the suggestions to
the possibly known genes greatly reduces the number of queries. Previously,
two expert knowledge elicitation methods have shown promising results for
prediction of a single outcome variable on textual data. We extend these
methods to the multi-output precision medicine setting. Next, we will in-
troduce the two alternative elicitation methods, the performances of which
will be evaluated and compared in the experiments.
3.2.1 Sequential experimental design
We introduce a sequential experimental design approach to select the next
(drug, feature) pair candidate to be queried for feedback from the expert,
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extending the work in [19]. Specifically, at each iteration t, we find the
pair where the feedback from the expert is expected to have the maximal
influence on the drug sensitivity prediction. The amount of information in
the expert feedback is measured by the Kullback–Leibler divergence (KL)
between the predictive distributions before and after observing the feed-
back. As the feedback value itself is unobserved before the actual query, an
expectation over the predictive distributions of the two types of feedbacks
is computed in finding the (drug, feature) pair (d∗,m∗) with the highest
expected information gain:
arg max
(d,m)/∈Ft−1
Ef˜reld,m,f˜dird,m|Dt−1
[
N∑
n=1
un,d,m,t
]
where
un,d,m,t = KL[p(y˜d | xn,Dt−1, f˜ reld,m, f˜dird,m) ‖ p(y˜d | xn,Dt−1)],
and Dt−1 = (Y ,X,Ft−1), observed drug sensitivities Y ∈ RN×D for N
patients and D drugs and the genomic features X ∈ RN×M , and Ft−1 is the
set of feedbacks given before the current query iteration. The summation
in n runs over the training data. The un,d,m,t measure the influence that
the feedback on feature m would have for the predictive distribution of the
nth patient for drug d. Once the query (d∗,m∗) is selected and presented
to the expert, the provided feedback is added to the set Ft−1 to produce Ft.
Queries where the expert is not able to provide an answer do not affect the
prediction model, but are added to the set so as not to be repeated.
Using the approximated posterior distribution (see Appendix A), the
posterior predictive distribution of the relevance and directional feedback,
p(f˜ reld,m, f˜
dir
d,m|Dt−1) = p(f˜ reld,m|Dt−1)p(f˜dird,m|Dt−1), follows a product of Bernoulli
distributions. The approximate posterior predictive distribution of y˜d fol-
lows a Gaussian distribution which makes the KL divergence calculation
simple. Calculating the expected information gain for each (drug, feature)
pair requires four posterior approximations, which would make the query
phase too costly. We follow a similar approach as in [19], and approximate
the posterior with the new feedbacks with only partial expectation propa-
gation updates.
3.2.2 User model
We introduce another approach for selecting the next (drug, feature) pair
candidate using a multi-armed bandit user model, extending the work in
[20]. The benefit of bandit user modeling is that the model learns from
the previous answers of the expert, and can guide the elicitation towards
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(drug, feature) pairs that will most likely get an answer from the expert
(exploitation), simultaneously balancing the trade-off with exploration of
uncertain pairs. We borrow this idea from the bandit literature (see, for
instance, [24]) to ensure that our user model concentrates the queries to the
(drug, feature) pairs that are likely to get an answer from the expert.
The user model predicts the expected response of the expert for each
query, in order to select the query on which we ask feedback next. We follow
a linear bandit model [21] and previous work on user intent modeling [25, 20],
where the estimate for each query is given by a dot product between a feature
vector describing the query (later description vector, zd,m), and an unknown
parameter that gives the relevance of the queries. The expected response is
then E[rd,m] = z
>
d,mv, and v at the iteration t is estimated using standard
linear regression vˆt = (Z
>
t Zt + λI)
−1Z>t (rt − b). Here λ is a regularizer, Zt
is a matrix containing description vectors zd,m of the pairs (d,m) that have
received feedback before or at the iteration t, and similarly rt contains the
t responses of the expert before or at the iteration t. The response of the
expert is rd,m = 1 if the feedback for the pair (d,m) is either ”relevant”,
directional or ”irrelevant”, and rd,m = 0 if the answer is ”I don’t know”.
The default response b is set to 0.5. The model chooses the pair for the next
query based on the upper confidence bound criterion [21, 26]. The details
of the user model are given in the Appendix B.
A simple, common choice for the description vector would be to use di-
rectly the patient measurements (as done in previous works, for instance,
for news article recommendation, where the description vector correspond-
ing to each news was given by the existing features in the news article
dataset and the user features [27]). However, in the more difficult case of
precision medicine, this simple description vector definition would not lead
to good performance due to the small sample size. Furthermore, previous
studies show that the use of auxiliary data is effective in both drug response
prediction [3] and interactive expert knowledge elicitation [20]. Thus, we
introduce description vectors for each (drug d, feature m) pair, constructed
by using prior knowledge in the form of KEGG pathways from Molecular
Signatures Database (MSigDB) [28], and the drug target genes from the
DrugBank [29].
Specifically, we first indicate if the feature is the target of the drug, and
then if the feature belongs in the same pathway as the target of the drug.
The description of mutation features is included as an indication of which
pathways the mutated gene belongs to. In our experiments (see Section 4),
this results in description vectors of length 133, including 1 description of
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the feature type (mutation or a cytogenetic marker), 2 descriptions of the
(drug, feature) pair, and 130 KEGG pathways containing any of the included
genes, specified in Section 4.2.
4 Experiments
In order to evaluate the proposed methods, we apply them to real patient
data and use feedback from well-informed experts to simulate sequential
knowledge elicitation. Details of the data set and the expert feedback col-
lection are presented in the next section, followed by the experimental results
showing the effectiveness of the methods in practice.
4.1 Experimental methods
We used a complete set of measurements on ex vivo drug response, somatic
mutations and karyotype data (cytogenetic markers), generated for a cohort
of 51 multiple myeloma patient samples. Drug responses are presented as
Drug sensitivity scores (DSS) as described in [30] and were calculated for
308 drugs that have been tested in 5 different concentrations over a 1000-
fold concentration range. Somatic mutations were identified from exome
sequencing data and annotated as described earlier in [31].
We focus our analysis on 12 targeted drugs, grouped in 4 groups based on
their primary targets (BCL-2, Glucocorticoid, PI3K/mTOR, and MEK1/2).
This results in data matrices of 51 × 12 (samples vs. drugs), 51 × 3025
(samples vs. mutations), and 51× 7 (samples vs. cytogenetic markers). All
data are normalized to have zero mean and unit variance. In this paper we
ask the experts only about the somatic mutations and cytogenetics markers,
which the experts know better and hence need to spend less time on in the
experiments. We will extend to molecular features with less well known
effects, such as gene expression, in follow-up work.
We use leave-one-out cross-validation1 to estimate the performances of
the drug sensitivity prediction models, with the concordance index (C-
index; the probability of predicting the correct order for a pair of samples;
higher is better)2 [32, 3] and the mean squared error (MSE; lower is bet-
ter) as the performance measures. MSE values are given in the normalized
1That is, in computing the predictions for each patient, that particular patient is not
used in learning the prediction model.
2We note that C-index computed from leave-one-out cross-validation can be biased as it
compares predictions for pairs of samples. We do not expect this to favour any particular
method.
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DSS units (zero mean, unit variance scaling on training data). Bayesian
bootstrap [33] over the predictions is used to evaluate the uncertainty in
pairwise model comparisons: in particular, we compute the probability
that model M1 is better than model M2 as Pr(M1 is better than M2) =
1
B
∑B
b=1 I(M1 is better than M2 in bootstrap sample b), where I(C) = 1 if
condition C holds and 0 otherwise [34].
The hyperparameters of the prediction model were set as ασ = 4, βσ = 4,
αρ = 1, βρ = 2, µ = −2, ω2 = 12 , and αpi = 9, βpi = 1 to reflect relatively
vague information on the residual variance (roughly higher than 0.5), a
minor preference for sparse models and moderate effect sizes, and the a
priori quality of the expert knowledge as 9 correct feedbacks out of 10. The
regularization in the user model is λ = 10−3, following the work [20].
4.2 Feedback collection
We expect that the experts can give feedback on the relevance and the di-
rection of the putative effect of features in predicting the response to a drug.
As observed in practice, the effect of a feature is often specific to a certain
type of drug, therefore, we decided to elicit feedback on (drug, feature) pairs.
Furthermore, we note that the experts indicated that the same feedback ap-
plies to all drugs in the same drug group. Specifically, we collected feedback
from two well-informed experts of multiple myeloma, using a form contain-
ing 161 mutations known to be related to cancer [35], and 7 cytogenetic
markers. The experts were asked to give feedback specific to 12 targeted
drugs, grouped by the targets (BCL-2, Glucocorticoid, PI3K/mTOR, and
MEK1/2). The answer counts by feedback type can be found in the Ap-
pendix C. The experts were instructed not to refer to external databases
while completing the feedback form, in order to collect their (tacit) prior
knowledge on the problem and make the task faster for them.
4.3 Simulated user experiment
We simulate sequential expert knowledge elicitation by iteratively querying
(drug, feature) pairs for feedback, and answering the queries using the pre-
collected feedback described in Section 4.2. At each iteration, the models
are updated and the next pair is chosen, based on the feedback elicited up to
that iteration, and the measurement data set which does not change. We run
three simulations for comparing the elicitation methods: two where the pairs
are chosen using one of the methods presented in Sections 3.2.1 and 3.2.2,
and one where the pair is chosen randomly. The pairs are selected without
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replacement from the 2016 (= 12 × 168) pairs included in the feedback
collection. The rest 2864 mutations are not queried for feedback, but all
3025 are included in the prediction model.
4.4 Results
We present here the two main results of the experiments. Further supple-
mentary results can be found in Appendix D.
Expert knowledge elicitation improves the accuracy of drug sen-
sitivity prediction. Table 1 establishes the baselines by comparing the
prediction model we use, the spike-and-slab regression model without expert
feedback, to constant prediction of training data mean, ridge regression, and
elastic net regression3. Elastic net has poor performance with regard to MSE
on this dataset. The ridge and the spike-and-slab models have comparable
performances, with bootstrapped probabilities of 0.87 of ridge being better
in the C-index and 0.42 in MSE.
Table 2 compares the spike-and-slab model without feedback to the mod-
els with all expert feedback. Knowledge of both of the experts improves the
predictions. The model with feedback from the senior researcher has 7%
higher C-index and 8% lower MSE compared to the no feedback model and
is confidently better according to the bootstrapped probabilities (0.98 for C-
index and 0.95 for MSE). The predictions improve in all of the 12 drugs that
were considered in the experiment. Detailed results of drug-wise predictions
are provided in Appendix D.
Table 1: Performance of drug sensitivity prediction without expert feedback.
Values are averaged over the 12 drugs. Best result on each row has been
boldfaced.
Data mean Ridge Elastic net Spike-and-slab
C-index 0.50 0.62 0.60 0.61
MSE 1.06 0.94 1.00 0.93
Sequential knowledge elicitation reduces the number of queries
required from the expert. In the results presented so far, the experts
had evaluated all (drug, feature) pairs and given their answers. However,
sequential knowledge elicitation has the potential to reduce this workload
significantly. We compare the effectiveness of the elicitation methods de-
3Ridge regression and elastic net are implemented using the glmnet R-package [36]
with nested cross-validation for choosing the regularization parameters.
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Table 2: Predictive performance of spike-and-slab regression with and with-
out expert feedback. Values are averaged over the 12 drugs.
No feedback Doctoral candidate Senior researcher
C-index 0.61 0.63 0.65
MSE 0.93 0.92 0.86
Number of expert feedbacks on (drug,feature) pairs
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Figure 2: Performance improves faster with the active elicitation meth-
ods than with randomly selected feedback queries. The curves show mean
squared errors as a function of the number of iterations for the three query
methods, with feedback of the senior researcher (left) and doctoral candidate
(right). In each iteration a (drug, feature) pair is queried from the expert.
The 50 independent runs of randomly selected queries are shown in red, and
the average in thick red line.
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veloped in this paper using a simulated user experiment (see Section 4.3).
The results in Figure 2 show that both methods achieve faster improve-
ment in prediction accuracy than the random selection, as a function of the
amount of feedback. We use Area Under the MSE Curves (AUC) to eval-
uate the significance of the improvements in predictions of our knowledge
elicitation methods, compared to the random selection method4. With the
senior researcher feedback, p ≤ 0.02 for both methods , whereas with the
doctoral candidate feedback p ≤ 0.02 for the sequential experimental design
and p = 0.35 for the bandit user model. With sequential knowledge elici-
tation, 50 % of the final improvement is reached in the first 496 (43) and
191 (562) feedbacks, for the experimental design and bandit user model re-
spectively, using Senior researcher feedback (Doctoral candidate feedback).
For a comparison, an average of 1139 (1228) feedbacks are required for sim-
ilar accuracy if the queries are chosen randomly. Thus, on average, the
sequential experimental design requires only 23% of the number of queries
compared to random, and the bandit user model 32%, to achieve half of the
potential improvement.
5 Conclusion
In this work we show, for the first time, that sequential expert knowledge
elicitation improves drug sensitivity prediction in precision cancer medicine.
We also show in a simulated user experiment with real expert feedback that
the proposed algorithms can elicit knowledge from experts efficiently. The
results indicate that expert knowledge can be very beneficial and, hence,
should be taken into account in modeling tasks of precision medicine. The
doctors and researchers are analyzing the data regardless of the advances in
the automated methods, and to not take their knowledge and expertise into
account is to neglect one possible source of data in a case where the lack of
data is a significant problem.
Our results were based on on knowledge elicited from two experts only.
Nevertheless, a significant improvement in knowledge elicitation performance
was observed for each of them even individually. In the future we will carry
out a wider study to thoroughly quantify the effect of expert feedback, and
to investigate further the initial observations about the impact of the type of
feedback and the level of seniority of the experts. We note that the experts
in this study had seen the data before, but to minimize the risk of overfitting
they were instructed to answer based on knowledge without seeing the data,
4We compare the AUC values of our knowledge elicitation methods to the empirical
distribution of the AUC values of 50 independent runs of the random selection method.
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and in the follow-up work we will recruit experts who are completely naive
as to the particular data.
We found that the most efficient elicitation method was different for the
two experts. An obvious next question is how to combine the two elicita-
tion methods to optimally utilize the complementary principles in them. In
addition, we have shown here the improvement in sparse linear regression
models. The next step will be to extend the method to more complex non-
linear models, and study how to maximally benefit from the responses of
multiple experts.
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Figure 3: Plate notation of the prediction model (right) and feedback obser-
vations (left) as introduced in Section 3.1 and Appendix A. The feedbacks
f rel and fdir are sequentially queried from the expert based on an expert
knowledge elicitation method.
Appendix A. Prediction model
Sparse linear regression models are used to predict the drug sensitivities
based on the genomic features. Let yn,d be the sensitivity of the nth patient
for drug d, and xn ∈ RM be the vector of the patient’s M genomic features.
We assume a Gaussian observation model:
yn,d ∼ N(w>d xn, σ2d),
where the wd ∈ RM are the regression weights and σ2d is the residual vari-
ance. A sparsity-inducing spike-and-slab prior [22, 23] is put on the weights:
wd,m ∼ γd,m N(0, τ2d,m) + (1− γd,m)δ0,
where γd,m is a binary variable indicating whether the mth feature is relevant
(i.e., wd,m drawn from a zero-mean Gaussian prior with variance τ
2
d,m) or
not (wd,m is set to zero via the Dirac delta spike δ0) when predicting for
the dth drug. The prior probability of relevance ρd controls the expected
sparsity of the model via the prior
γd,m ∼ Bernoulli(ρd).
The model is completed with the hyperpriors:
σ−2d ∼ Gamma(ασ, βσ),
ρd ∼ Beta(αρ, βρ),
τd,m ∼ Log-N(µ, ω2).
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Settings for the values of the hyperparameters are discussed in Section 4.1.
Given the observed drug sensitivities Y ∈ RN×D for N patients and D
drugs and the genomic featuresX ∈ RN×M , the posterior distribution of the
model parameters θ = (w,γ,ρ, τ 2,σ2) is computed via the Bayes theorem
as
p(θ | Y ,X) = p(Y |X,w,σ
2)p(w |γ, τ 2)p(γ |ρ)p(ρ)p(τ 2)p(σ2)
p(Y |X) .
The posterior distribution of w together with the observation model is then
used to compute the predictive distribution of the drug sensitivities y˜ =
[y˜1, . . . , y˜D]
> for a new data point x˜:
p(y˜ | Y ,X, x˜) =
∫
p(y˜ | x˜,w,σ2)p(θ | Y ,X)dθ. (1)
Expert knowledge is incorporated into the model via feedback observa-
tion models [19]. The relevance feedback f reld,m ∈ {0, 1} (0 denotes irrelevant,
1 relevant) of feature m for drug d follows
f reld,m ∼ γd,m Bernoulli(pireld ) + (1− γd,m) Bernoulli(1− pireld ),
where pireld is the probability of the expert being correct. For example, when
the mth feature for drug d is relevant in the regression model (i.e., γd,m = 1),
the expert would a priori be assumed to say f reld,m = 1 with probability
pireld . In the model learning (i.e., calculating the posterior distribution in
Equation 2 below), once the expert has provided the feedback based on
his or her knowledge, pireld effectively controls how strongly the model will
change to reflect the feedback.
The directional feedback fdird,m ∈ {0, 1} (0 denotes negative weight, 1
positive) follows
fdird,m∼I(wd,m≥0)Bernoulli(pidird )+I(wd,m<0)Bernoulli(1−pidird ),
where I(C) = 1 when the condition C holds and 0 otherwise, and pidird is
again the probability of the expert being correct. For example, when the
weight wd,m is positive, the expert would a priori be assumed to say f
dir
d,m = 1
with probability pidird .
To simplify the model, we assume pid = pi
dir
d = pi
rel
d and set a prior on pid
as
pid ∼ Beta(αpi, βpi).
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Given the data Y and X and a set of observed feedbacks F encoding
the expert knowledge, the posterior distribution is computed as
p(θ | D) =p(Y |X,w,σ
2)p(w | γ, τ 2)p(γ | ρ)p(ρ)p(τ 2)p(σ2)
p(Y ,F |X)
× p(F | γ,w,pi)p(pi), (2)
whereD = (Y ,X,F ) and θ now includes also pi. The predictive distribution
follows from Equation 1. Figure 3 shows the plate diagram of the model.
The computation of the posterior distribution is analytically intractable.
The expectation propagation algorithm [37] is used to compute an efficient
approximation. In particular, the posterior approximation for the weights
w is a multivariate Gaussian distribution and the predictive distribution for
y˜d is also approximated as Gaussian [38, 19]. The mean of the predictive
distribution is used as the point prediction in the experimental evaluations
in Section 4.
Appendix B. User model
The user model chooses the pair for the next query based on upper confidence
bound criterion. The upper confidence bound at iteration t is computed as
r
UCB (t)
d,m = r
(t)
d,m + c
(t)
d,m, where the confidence of the response is computed as
in [26]:
c
(t)
d,m = ρt
√
z>d,m(ZtZ
>
t + λI)
−1zd,m, ρt =
√
1
2
log
(2tK
δ
)
.
Here K is the number of (drug, feature) pairs, and δ = 0.05 defines that the
bound holds with the probability 1− δ. The user model is initialized using
regression weights from the prediction model as pseudo-feedback, with lower
weight such that one feedback from an expert corresponds to 10 pseudo-
feedbacks, similarly as in [20].
Appendix C. Feedback collection
The answer counts by feedback type are summarized in Table 3 for both of
the experts.
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Table 3: Feedback type and count, given to the 2016 (drug, feature) pairs
by the experts. SR = Senior researcher, DC = Doctoral candidate.
Answer SR DC
Relevant, positive correlation 192 47
Relevant, negative correlation 14 34
Relevant, unknown correlation direction 26 372
Not relevant 13 0
I don’t know 1771 1563
Appendix D. Further results
Feedback on the direction of the putative effect is more effective
than general relevance feedback. We also assess the importance of
the type of the feedback by comparing a spike-and-slab model with only
relevance feedback (interpreting potential expert knowledge on the direction
only as relevance) to a model with both types of feedback. Table 4 shows
that the directional feedback improves the performance markedly, especially
in the case of the senior researcher (who gave more directional feedback than
the doctoral candidate; see Table 3). The bootstrapped probabilities are 0.70
in the C-index and 0.71 in MSE in favour of both types of feedback compared
to only relevance feedback for the doctoral candidate and, similarly, 0.93 and
0.93 in the case of the senior researcher.
Table 4: Performance of drug sensitivity prediction with only relevance feed-
back and with relevance and directional feedback. Values are averaged over
the 12 drugs.
Doctoral candidate Senior researcher
Relevance only Both Relevance only Both
C-index 0.62 0.63 0.62 0.65
MSE 0.93 0.92 0.93 0.86
Use of biological prior information from databases benefits the
user modeling. In the sequential knowledge elicitation with bandit user
model, the queries are chosen based on expert’s earlier answers and fea-
ture descriptions. However, the expert’s feedback still defines which of the
queried pairs are, in fact, relevant to the prediction task. Next we investi-
gate how much the user models improve when using auxiliary biological in-
formation from databases. We form description vectors, as described in Sec-
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tion 3.2.2, from the patient data used in the prediction task or, alternatively,
from pathway and drug target information available in the databases. We
compare the two alternatives in how well they discriminate the (drug, fea-
ture) pairs for which the expert was able to provide feedback from those
where the answer was ’I don’t know’. The results in Table 5 show that us-
ing biological prior information improves especially the recall of the useful
(drug, feature) pairs, which means that the model finds a greater proportion
of the (drug, feature) pairs that got feedback.
Table 5: Precision and recall of classifying (drug, feature) pairs using descrip-
tion vectors from patient sample data and from auxiliary data of pathways
and drug targets. SR = Senior researcher, DC = Doctoral candidate
Patient data Pathway and target information
SR Precision 1.00 0.89
Recall 0.27 0.42
DC Precision 0.88 0.90
Recall 0.23 0.46
Drug-wise overview of the results. Table 6 shows the effect of expert
feedback on the 12 drugs used in the study. The predictions improved in
all of the drugs, and the improvement is in general greater with the senior
researcher’s feedback. On the other hand, we observed that the type of
feedback each expert gave was different, as the senior researcher provided
more directional feedback than the doctoral candidate, and the doctoral
candidate provided more relevance feedback (Table 3). The greater number
of directional feedback could explain the greater overall improvement with
senior researcher’s feedback, as we have already observed that directional
feedback is more effective than relevance feedback.
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Table 6: Predictive performance of individual drugs with and without expert
feedback.
NF = No feedback, DC = Doctoral candidate, SR = Senior researcher.
C-index MSE
Drug NF DC SR NF DC SR
Pimasertib 0.63 0.60 0.68 0.78 0.83 0.67
Refametinib 0.67 0.64 0.68 0.80 0.85 0.71
Trametinib 0.66 0.65 0.70 0.84 0.87 0.71
Dexamethasone 0.65 0.71 0.68 0.96 0.91 0.96
Methylprednisolone 0.65 0.69 0.63 0.95 0.90 0.96
AZD2014 0.61 0.60 0.68 0.94 0.93 0.80
Dactolisib 0.59 0.59 0.66 0.97 0.92 0.86
Idelalisib 0.45 0.55 0.52 1.12 1.09 1.25
PF.04691502 0.57 0.62 0.64 1.00 0.96 0.90
Pictilisib 0.57 0.64 0.64 0.95 0.88 0.87
Temsirolimus 0.59 0.57 0.63 0.94 1.02 0.78
Venetoclax 0.66 0.71 0.68 0.95 0.83 0.88
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